Parkinson's disease, primates, and gene therapy: vive la différence?
作者信息
Lewis Travis B, Standaert David G
出版信息
Mov Disord. 2011 Jan;26(1):2-3. doi: 10.1002/mds.23544. Epub 2010 Dec 17.
Abstract
摘要
相似文献
1
Parkinson's disease, primates, and gene therapy: vive la différence?
Mov Disord. 2011 Jan;26(1):2-3. doi: 10.1002/mds.23544. Epub 2010 Dec 17.
2
Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.
Mov Disord. 2011 Jan;26(1):27-36. doi: 10.1002/mds.23442. Epub 2010 Nov 18.
3
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.
Lancet Neurol. 2008 May;7(5):400-8. doi: 10.1016/S1474-4422(08)70065-6. Epub 2008 Apr 2.
4
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.
Lancet Neurol. 2010 Dec;9(12):1164-1172. doi: 10.1016/S1474-4422(10)70254-4. Epub 2010 Oct 20.
5
Gene therapy for Parkinson's disease: do we have the cure?
Lancet Neurol. 2010 Dec;9(12):1142-1143. doi: 10.1016/S1474-4422(10)70256-8.
6
Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease.
Neurobiol Aging. 2013 Jan;34(1):35-61. doi: 10.1016/j.neurobiolaging.2012.07.018. Epub 2012 Aug 24.
7
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial.
Ann Neurol. 2015 Aug;78(2):248-57. doi: 10.1002/ana.24436. Epub 2015 Jun 10.
8
Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's disease.
J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1210-1218. doi: 10.1136/jnnp-2020-322904. Epub 2020 Jul 30.
9
Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease.
Brain. 2020 Mar 1;143(3):960-975. doi: 10.1093/brain/awaa020.
10
The delivery of tyrosine hydroxylase accelerates the neurorestoration of Macaca Rhesus model of Parkinson's disease provided by Neurturin.
Neurosci Lett. 2012 Aug 22;524(1):10-5. doi: 10.1016/j.neulet.2012.06.063. Epub 2012 Jul 2.
引用本文的文献
1
How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
J Neurochem. 2016 Oct;139 Suppl 1(Suppl 1):131-155. doi: 10.1111/jnc.13627. Epub 2016 May 4.
2
Formation of α-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes.
Mol Biol Cell. 2014 Dec 15;25(25):4010-23. doi: 10.1091/mbc.E14-02-0741. Epub 2014 Oct 8.
本文引用的文献
1
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.
Lancet Neurol. 2010 Dec;9(12):1164-1172. doi: 10.1016/S1474-4422(10)70254-4. Epub 2010 Oct 20.
2
Target validation: the Parkinson disease perspective.
Dis Model Mech. 2010 May-Jun;3(5-6):259-62. doi: 10.1242/dmm.004192.
3
Axonal transport defects in neurodegenerative diseases.
J Neurosci. 2009 Oct 14;29(41):12776-86. doi: 10.1523/JNEUROSCI.3463-09.2009.
4
Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys.
Hum Gene Ther. 2009 Dec;20(12):1627-40. doi: 10.1089/hum.2009.103.
5
Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.
Neurosurgery. 2009 Apr;64(4):602-12; discussion 612-3. doi: 10.1227/01.NEU.0000340682.06068.01.
6
Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity.
Mol Ther. 2009 Jun;17(6):980-91. doi: 10.1038/mt.2009.45. Epub 2009 Mar 10.
7
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.
Lancet Neurol. 2008 May;7(5):400-8. doi: 10.1016/S1474-4422(08)70065-6. Epub 2008 Apr 2.
8
Design of clinical trials of gene therapy in Parkinson disease.
Exp Neurol. 2008 Jan;209(1):41-7. doi: 10.1016/j.expneurol.2007.08.012. Epub 2007 Aug 31.
9
Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal.
J Neurosurg. 2007 Apr;106(4):614-20. doi: 10.3171/jns.2007.106.4.614.
10
Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.
J Neurochem. 2007 Mar;100(6):1449-57. doi: 10.1111/j.1471-4159.2006.04310.x. Epub 2007 Jan 4.
Zotero 插件